Myricx Deal Highlights the Early-Stage Value of U.K. Oncology Startups

In cancer drug development, what is truly expensive is not necessarily only molecules that have entered late-stage clinical trials, but platforms that are capable of changing the design logic of an entire class of drugs. Novartis has agreed to acquire U.K. cancer biotech company Myricx Bio in a deal worth up to $1.5 billion, showing that competition in antibody-drug conjugates (ADCs) no longer revolves only around “which target the antibody finds,” but has also extended to whether the cytotoxic payload itself can be more precise and more controllable.

According to multiple media reports, the deal includes an upfront payment of $1.1 billion, plus up to $400 million in milestone payments. Myricx is headquartered in London and is rooted in research from Imperial College London and the Francis Crick Institute. It was founded in 2019 by Ed Tate, Roberto Solari, and Andrew Bell. Compared with ADC products that have already reached commercialization, Myricx is more like an early-stage platform company betting on fundamental chemistry and cell biology.

At the core of Myricx is its N-myristoyltransferase inhibitor (NMTi) payload platform. N-myristoyltransferase is involved in protein lipid modification and affects multiple cellular functions; if such inhibitors are used as toxic payloads for ADCs, in theory the antibody could bring the drug near tumor cells and then release a killing molecule with a different mechanism of action. The focus described by Fiona Marshall, head of Novartis Biomedical Research, is also that this “differentiated mechanism” could allow ADCs to expand into more tumor settings.

The key here is not the term ADC itself, but the boundaries of tolerability and drug resistance. Traditional payloads often rely on pathways such as microtubule inhibition or DNA damage. Although efficacy has been demonstrated by multiple drugs, toxicity, bystander effects, tumor heterogeneity, and post-relapse resistance still limit the usable dose and the range of patients who can receive them. If Myricx’s NMTi strategy proves viable, its value would lie in providing another language for cell killing; however, the publicly available information remains limited and is still insufficient to judge its therapeutic window, safety, and tumor selectivity in humans.

The U.K. biotech ecosystem has therefore become another main thread in the transaction. Myricx previously completed a £90 million Series A financing led by Novo Holdings and Abingworth, with participants including British Business Bank, Cancer Research Horizons, Eli Lilly, and existing investors. This combination shows that early-stage technologies derived from universities and research institutions, if they can address pipeline gaps for large pharmaceutical companies at the mechanistic level, may be rapidly incorporated into the R&D map of multinational drugmakers even before mature clinical assets have formed.

For Novartis, acquiring Myricx is not a simple addition of a single drug candidate, but a way to bring a payload platform into its internal oncology pipeline. The ADC market has heated up in recent years because of multiple successful products and major licensing deals, but the hotter the competition becomes, the harder it is to stand apart using similar targets and similar toxic payloads alone. Buying a company that is still at a relatively early stage amounts to taking on scientific risk through M&A while also securing control before the platform matures.

However, the deal value should not be misread as a guarantee of clinical success. Whether NMTi payloads can maintain sufficient selectivity across different tumors, whether difficult-to-manage normal tissue toxicity will emerge, and whether they truly improve efficacy or tolerability compared with existing ADCs still require animal data, early human trials, and longer-term validation. What this acquisition most clearly reveals is not that a new drug is about to rewrite treatment, but that the next stage of the cancer drug race is moving toward a deeper layer of molecular design.